Arrowhead Research: Fiscal Q4 Earnings Snapshot

Arrowhead (ARWR) Q4 2026 Earnings Call Transcript

Plozasiran launch prep and a multibillion sHTG opportunity come into focus.

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2026 Earnings Call November 12, 2026 4:30 PM ESTCompany ParticipantsVincent Anzalone - Head of Investor Relations...

Arrowhead Pharmaceuticals Q4 Earnings Call Highlights

Arrowhead Pharmaceuticals (NASDAQ:ARWR) is preparing for a potential U.S. launch of its drug REDEMPLO in a larger patient population in the second quarter of 2027, as the company works to turn growing prescription demand for the medicine into paid treatments. On its fiscal 2026 earnings call, manag

Arrowhead Research: Fiscal Q4 Earnings Snapshot

PASADENA, Calif. (AP) — PASADENA, Calif. (AP) — Arrowhead Research Corp. (ARWR) on Thursday reported a loss of $428 million in its fiscal fourth quarter.

Arrowhead Posts $450.82 Million in Revenue as GAAP EPS Misses

GAAP earnings per share was -$5.11, $1.51 below estimates; revenue missed estimates by $13.32 million.

Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results